ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development
Collaboration will expand access to high sensitivity NULISA immunoassays for clinical biomarker analysis.
ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a leader in ultra-sensitive immunoassay technologies, today announced a partnership in the development of customized biomarker assay solutions using Alamar’s NULISA™ (Nucleic Acid Linked Immuno-Sandwich Assay) immunoassay platform and ARGO™ HT System. This collaboration aims to provide advanced tools for the detection and quantification of critical biomarkers to support neurological disease therapeutic development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241027884281/en/
ADx NeuroSciences logo (Graphic: Business Wire)
Under the terms of the partnership, Alamar Biosciences and ADx NeuroSciences will combine their respective expertise to provide tailored assay solutions to meet the specific needs of pharmaceutical companies advancing novel therapeutics for neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS.
"We are excited to partner with ADx NeuroSciences, a recognized leader in the field of neurodegenerative biomarker research," said Dr. Yuling Luo, Chairman and CEO of Alamar Biosciences. "By combining our NULISA platform's ultra-sensitive detection capabilities with ADx’s extensive expertise in neuroscience antibody and assay development, we aim to accelerate the development of biomarker assays that can facilitate the development and approval of disease modifying therapies for neurodegenerative diseases.”
Koen Dewaele, CEO of ADx NeuroSciences, commented, "Our collaboration with Alamar Biosciences marks a significant step forward in our mission to support pharmaceutical companies advancing their therapeutic programs. Every phase in the search for a therapeutic, from preclinical work up to the launch of the ultimate drug, requires specific biomarker tools. By working with various technology platforms, we are able to make our biomarker assays available on the right technology at the right time. By adding the NULISA platform with its remarkable sensitivity to our range of possible platforms, it enforces our capabilities to support our pharma network in their search for tailor-made biomarkers."
This strategic collaboration highlights both companies' commitment to advancing biomarker detection and expanding the possibilities for early diagnosis and treatment of neurodegenerative diseases. By harnessing the power of the NULISA platform, Alamar Biosciences and ADx NeuroSciences aim to deliver cutting-edge solutions that will benefit clinical research and aid in the development of novel therapeutics.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA Platform along with the ARGO™ HT System works seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the high sensitivity protein detection technologies on the market today. For more information, please visit alamarbio.com.
About ADx NeuroSciences NV
ADx NeuroSciences is specialized in the research and development of neurodegenerative biomarker tools for diseases such as Alzheimer's and Parkinson's. Its expertise is used by pharmaceutical and diagnostic companies across the world for the conception, development, production, and worldwide commercialization of novel biomarkers, supporting the development of promising drugs, either by monitoring the drug effect or by selecting the right patients at a very early stage of the disease. These assays can be applied to a variety of platforms from research up to IVD use. The company was founded in 2011 and was acquired in 2022 by Fujirebio, a member of H.U. Group Holdings Inc., which is listed on the Tokyo Stock Exchange (TSE: 4544). For more information, please visit www.adxneurosciences.com.
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality IVD testing with more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products. Fujirebio was the first company to develop and market CSF biomarkers for AD testing, under the Innogenetics brand, over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated neurodegenerative disease assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools. For more information, please visit www.fujirebio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241027884281/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeiGene Mourns Death of Beloved Board Member Donald Glazer28.10.2024 11:00:00 CET | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to share the news that Donald Glazer recently passed away. Don was a Board member and the chair of the nominating and corporate governance committee. Co-founder, Chairman and CEO John V. Oyler issued the following statement: “We are saddened by the passing of our dear friend, Don Glazer. He helped guide the founding of the company in 2010 and was an ardent supporter of our mission to deliver innovative medicines faster and more affordably to patients around the world. His impact from a professional and personal perspective is immeasurable, and he will be deeply missed by all of us who benefited from his extensive experience, sound judgment and wise counsel. We extend our heartfelt condolences to his family during this difficult time.” Mr. Glazer served as a passionate BeiGene Board member, building connections amongst broad networks of cancer doctors – including his own – around the world. He
Transition Industries LLC and Mitsubishi Gas Chemical announce Letter of Intent for a long-term Methanol Sales Agreement from the Pacifico Mexinol project in Sinaloa, Mexico28.10.2024 10:00:00 CET | Press release
Transition Industries LLC announced that it has signed a Letter of Intent (LOI) with Mitsubishi Gas Chemical Company, Inc. (MGC) to enter into a long-term Methanol Sales Agreement (MSA). Under the MSA, Transition Industries intends to supply MGC approximately 1 million MT per annum of ultra-low carbon methanol from its Pacifico Mexinol project, a 6,145 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico, expected to be in operation in 2028. Transition Industries is jointly developing Pacifico Mexinol with the International Finance Corporation (IFC), a member of the World Bank Group. The terms of the LOI and MSA were not disclosed. When it initiates operations, Pacifico Mexinol is expected to be the largest single ultra-low carbon chemicals facility in the world - producing approximately 350,000 MT of green methanol and 1.8 million MT of blue methanol annually from natural gas with carbon capture. Rommel Gallo, CEO of Transition Industries, commented: “We are pleas
AD Ports Group Is a Leading Driver of Economic Diversification and Non-Oil GDP in Abu Dhabi and UAE: New Study28.10.2024 10:00:00 CET | Press release
AD Ports Group's activities in the UAE across various sectors, including industry, trade, and logistics contributed 22.9% to Abu Dhabi's non-oil economy, with a total AED 132.7 billion in 2022 at current prices, according to Oxford Economics.The Group's total contribution to UAE non-oil economy was an estimated AED 150.6 billion at current prices, equivalent to 11.6% in 2022 AD Ports Group (ADX: ADPORTS), the leading facilitator of global trade, logistics, and industry in the Arabian Gulf and Red Sea, unveiled a new economic impact report that underscored the Group’s growing role as a driver of economic diversification in Abu Dhabi and the UAE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241027616586/en/ Captain Mohamed Juma Al Shamisi, Managing Director and Group CEO, AD Ports Group (Photo: AETOSWire) The results of the study conducted by Oxford Economics, which was based on 2022 data, illustrated in fresh detail the Gro
Network International Signs Strategic Partnership With Ant International to Provide New Payment Solutions to Businesses in MEA, Driving Financial Inclusion28.10.2024 08:03:00 CET | Press release
Network International (Network), a leading enabler of digital commerce in the Middle East and Africa (MEA), and leading global digital payment and financial technology provider Ant International, have signed a Memorandum of Understanding to extend innovative digital payment solutions to businesses in the Middle East and Africa, driving digital transformation and financial inclusion in the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241027110387/en/ (L-R) Mr Nandan Mer, CEO, Network International; H.E. Jamal Abdulla AlSuwaidi, Ambassador of the UAE to Singapore; Mr Peng Yang, CEO, Ant International (Photo: Business Wire) The ceremony was witnessed by H.E. Jamal Abdulla AlSuwaidi, the Ambassador of The United Arab Emirates to the Republic of Singapore. As part of the partnership, Network will leverage Alipay+ Wallet Tech solutions such as developing e-wallet capabilities to better serve its customers across MEA. Ali
EH Group Launches EH-TRACE 250kW Fuel Cell System28.10.2024 08:00:00 CET | Press release
Decarbonising high power applications has never been easier. Following several years of intense development, EH Group is proud to launch its EH-TRACE M-250kW Fuel Cell System. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241028178580/en/ EH TRACE - 250kW Fuel Cell System (Photo: Business Wire) A plug & play power solution featuring EH's advanced stack technology and AI/ML based control system. It offers unrivalled performance, versatility and cost reduction potential - based on our single stack platform EH-87 and single balance of plant. A fully integrated power module, it includes fuel cell system, heat exchanger and DC/DC for ease of implementation. Modular in design, it can easily be configured for up to 3MW power in a standard 40ft container. Our uniquely simplified FC system architecture delivers a minimum electrical efficiency of >50%. It has been developed for high power stationary applications such as data-centres,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom